1

NCI’s Alliance for Nanotechnology in Cancer Program and Resources for Cancer

Nanotechnology Research

Stephanie A. Morris, Ph.D. Program Director

Office of Cancer Nanotechnology Research (OCNR) National Cancer Institute/NIH

UPenn Nano/Bio Interface Center September 15, 2015

2

Nanotechnology Applications to Cancer: • Potential to revolutionize biomedicine by manipulating materials at the

nanoscale (unique physical, chemical, biological features that differ from bulk)

• Combine innovations in nanomaterials and cancer biology to develop new cancer solutions

• Early detection of disease – Sensors – Imaging

• Delivery of therapeutics – Local and systemic – Improved efficacy – Post-therapy monitoring

• New research tools to enhance understanding of disease

RNAi-functionalized gold nanoparticles (Mirkin, Northwestern)

NCI Alliance for Nanotechnology in Cancer (Alliance)

• Supported by NCI’s Office of Cancer Nanotechnology Research • The Alliance works in concert with other NCI advanced technology initiatives to

provide the scientific foundation and team science required to transform cancer research and benefit the patient

Alliance for Nanotechnology in Cancer:

3

Phase II Alliance Organization

The Alliance aims to: • Rapidly advance new nanotechnology discoveries into cancer clinical practice by

fostering multi-disciplinary approaches • Aid nanoparticle characterization and standardization of characterization

methods • Develop the next-generation of cancer researchers in the area of

nanotechnology

Centers for Cancer

Nanotechnology Excellence (CCNEs)

U54 Cooperative Agr.

Cancer Nanotechnology

Platform Partnerships U01 Cooperative Agr.

Multi-disciplinary Training K99/R00 Awards, R25

Awards

Nanotechnology Characterization Laboratory (NCL)

NCI Alliance Phase II

• Alliance’s development model—most promising strategies handed off to for-profit partners for effective translation and commercialization

• Phase I: 2005 – 2010 • Phase II: 2010 - 2015

Serves as national resource to aid regulatory review of cancer

nanotechnologies

4

Phase II Alliance Objectives

The Alliance focuses on techniques and tools for: • Multifunctional nanotherapeutics and post-therapy monitoring tools • Early diagnosis using in vitro assays and devices • In vivo imaging techniques for early detection and surgical guidance

research discovery

pre-clinical

clinical

• Focus on cancers characterized by low survival rates: pancreatic, ovarian, brain, lung

• Goal of advancing cancer prevention, diagnosis, and treatment

Key Research Goals: • Focus on improving diagnostic detection

and therapeutic index • Overcoming biological barriers (including the

microenvironment) and failure of therapy

5

Key Research Topics

• Nano-based vehicles for protein/nucleic acid/drug delivery – Improved pharmacokinetics, reduced toxicity – Targeted to tumor (passive (EPR) and active) – Protection from degradation

• Combination therapies within a single formulation

• Controlled Release of conjugated or encapsulated drug

• Design of vehicles that penetrate biological barriers

BIND Biosciences

Nanotherapeutics

In Vitro Assays/Devices and In Vivo Imaging Techniques

Integrated Blood Barcode Chip—Measurement of GBM biomarker panel (Heath and Hood, Caltech)

• Highly sensitive in vitro nanosensors (proteins, RNAs) to measure diagnostic or prognostic biomarkers

• Multiplexed, multi-modal imaging agents for diagnosis,

surgical resection, and therapeutic monitoring (e.g. In vivo enzyme activity-based assays)

6

NCI Alliance for Nanotechnology in Cancer, Phase II

Cancer Nanotechnology Training Centers (CNTCs; R25) (6) Pathway to Independence Award in Cancer Nanotechnology – K99/R00 (7)

Centers of Cancer Nanotechnology Excellence (CCNEs; U54) (9) Cancer Nanotechnology Platform Partnerships (CNPPs; U01s) (12)

Southeast

California

New England

Midwest

West-Southwest

7

Office of Cancer Nanotechnology Research: Interactions

• Alliance members also have opportunities to work together through topic-specific working groups (animal models, biotargeting) and Challenge Projects

• OCNR also facilitates interactions between Alliance investigators and other NCI/NIH programs, nanotechnology institutions and organizations

• Significant role in promoting nanotechnology applications to biomedicine by interacting with these programs, other federal agencies (e.g., through NNI) and the wider research community

Translating Genomic Targets in Cancer

Therapeutics Using Nanotechnology

• Connecting investigators in Alliance with investigators in other NCI programs--CTD2 Network

• Exchanging resources, meeting reciprocal needs

PAR-13-185: Image-guided Drug Delivery

in Cancer (R01)

• Developing funding opportunities with other Institutes—NCI and NIBIB

• Advance aspects of image-guided interventions

US-China Symposium on Nanobiology and

Nanomedicine

• Collaboration between NCI, other NIH Institutes, and the NCNST of China

• Explore collaborative opportunities and facilitate discussions on medical nanotechnologies

8

NCI Alliance Program - Achievements • Scientific Output

• More than 25 distinct nanomaterial delivery vehicles at various stages of maturity and numerous innovative technologies reported in the literature since 2011

• Over 1000 peer-reviewed journal papers and close to 100 patent filings and disclosures since 2011(close to 1500 papers and 300 patent filings since program start)

• Over 300 different nanoparticle formulations evaluated by the NCI’s Nanotechnology Characterization Laboratory (NCL)

• Clinical Translation

• over 75 companies in the space of diagnostics and therapy are associated with the program. Majority of them are start-ups.

• 17 on-going clinical trials are associated with program projects • Several companies are in IND or pre-IND discussions with US FDA

• Community Resources

• Support for clinical translation—NCL and TONIC consortium • Centralized databases of nanomaterial characterization information—

caNanoLab and Nanomaterial Registry web portals

9

Translational Support

• Public–private partnership • Corporate membership--14 industry members

(e.g. Janssen, AstraZeneca, Onyx Pharma, Teva), three patient advocacy group members (e.g., American Brain Tumor Association)

• Bringing Alliance research and TONIC members together

• Discussion forum for opportunities in nanotechnologies and strategies to accelerate translation to clinic

–Workshops –Showcasing of technologies –Joint, pre-competitive projects –Nanodrug Clinical Working Group—

Developing protocols to enable study of drug delivery in patients by imaging

Translation of Nanotechnology in Cancer Consortium (TONIC)

• Pre-clinical characterization of nanomedicines

• Three way agreement of NCI, FDA, and NIST • Supports extramural community • Assisted with characterization leading to six

IND or IDE filings with FDA

Nanotechnology Characterization Laboratory (NCL)

10

TONIC Consortium

• Two publications: – Prabhakar et al., 2013, Cancer Research--“Challenges and key considerations of the

Enhanced Permeability and Retention Effect for nanomedicine drug delivery in oncology”

– Gabizon et al., 2014, The Lancet—” Cancer nanomedicines: closing the translational gap”—strategic preclinical and clinical study designs to address the EPR effect question

• TONIC has been credited with facilitating: – interactions with NCL for TEVA and AstraZeneca – Research agreement between Cytimmune and AstraZeneca

Advisory Committee Joseph DeSimone (UNC), Robert

Langer (MIT), Chad Mirkin (Northwestern U),

Larry Tamarkin (Cytimmune), and Vladimir Torchilin (Northeastern U.)

http://nano.cancer.gov/collaborate/collaborating/nanotechnology.asp

11

Continue to Provide Assay Cascade Resource

Reformulation & cGMP

NCL as National Mission for Frederick National Laboratory for Cancer Research

Informing Regulatory • Equivalence testing for nanosimilars • Addressing FDA’s scientific questions • NBCDs

• Collaborations with Pharma, CMOs & industry consortia

Basic Research & Grand Challenges • Immunotox • Active targeting

Metrology & New Methods • Working with instrument manufacturers

• Provides “pharmaceutical mentorship” for materials scientists and engineers

• EU-NCL

Nanomaterials • Other indications, EHS, etc.

Transnational Collaboration

12

Nanotechnology Characterization Laboratory: Serving the Community

Standards development efforts in collaboration with NIST, ASTM, ISO, IANH

caNanoLab co-development

Crist et al., Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb)., 2013

NCL is the only lab evaluating the wide variety of platforms used in nanomedicine. Ten years of providing NCL Assay Cascade testing has given NCL expertise that is unique in the world.

Source and Types of Samples

http://ncl.cancer.gov

13

• NCL testing is tailored to the platform properties, API, route of administration, and intended therapeutic outcome of the individual nanomedicine

• Testing links physicochemical properties to biological outcomes.

• Characterized over 300 different nanomaterials and a wide range of platforms. Ten collaborators with products in clinical trials.

• An average of 15 active collaborations at any given time and characterizes an average of 75 samples each year

Assay Cascade Outcomes and Submission Process

Physicochemical In vitro

In vivo

http://ncl.cancer.gov Next application deadline—

December 1, 2015

Application process in two parts: • Part I—three to four page white paper

that describes strategy/concept • Part II—full proposal, will be asked of

researchers with white papers deemed of interest to NCL

Evaluation Criteria: • Primary criterion—demonstrated

efficacy in a biological system (in vitro, in vivo) relevant to cancer research

• Advantage over existing cancer therapies or diagnostics

• Other factors

14

• Realize importance of data sharing and re-use to enable knowledge discovery and improve the rational design of nanomaterials –access to datasets and protocols

Federal Agencies

•National Nanotechnology Initiative (NNI)

Community Interaction

•NCIP Nanotechnology Working Group

Databases •caNanoLab •Nanomaterial Registry

NNI Signature initiative on Nanoinformatics—Nanotechnology Knowledge Infrastructure (NKI): Purpose is to provide a community-based, solutions-oriented knowledge infrastructure by coordinating federal agencies; http://www.nano.gov/NKIPortal

Nanomaterial Data Curation Initiative—Developing data exchange standards, ontologies, community interest; capturing current curation practices and concerns; https://wiki.nci.nih.gov/display/ICR/Nanotechnology+Working+Group

Nanomaterial Data Storage and Sharing—NIH-supported data repositories that facilitate data sharing and re-use in the research community; http://nano.cancer.gov/collaborate/data/

Resources for Nanomaterial Data Sharing and Standards Development

15

NIH-Sponsored Data Repositories: caNanoLab and the Nanomaterial Registry

Aggregates data from: • Existing publicly-available databases • Patent literature • Manufacturer catalogs Minimal information about a nanoparticle (MIAN)—used to calculate compliance levels, record similarity

www.nanomaterialregistry.org

Supports the annotation of well characterized nanomaterials used in cancer research and treatment • Composition and physico-chemical

information • In vitro/in vivo characterizations • Protocols and publications

cananolab.nci.nih.gov • Started in 2006 • Joint NCI support—Office of Cancer

Nanotechnology Research, Center for Biomedical Informatics and Information Technology

• Started in 2011 • Joint NIH support—NIBIB, NCI,

NIEHS

16

cancer Nanotechnology Laboratory (caNanoLab) Data Portal

• Facilitate data sharing to expedite and validate

use of nanomaterials in biomedicine • Provides access to data, protocols, and

publications • In house curator; data submission directly by

users (access to data private or public) • Making strong efforts to curate from the broader

international community

http://cananolab.nci.nih.gov

Morris et al., 2015, Beilstein J Nanotechnol; Gaheen et al., 2013, Comput Sci Discov

Home Page

17

Nanomaterial Registry

• caNanoLab feeds into Registry • Archives research data on nanomaterials and their biological and environmental implications

• Tools to evaluate content—compliance levels, comparison tools

• Working on integrating modeling and simulation tools for Registry data analysis (nanoHub; http://nanohub.org/)

• Provides data export function to allow easy data download from site and working on data submission page/template; boilerplate text for NSF/NIH data management plans

https://www.nanomaterialregistry.org/

Supported by

18

• Elsevier’s Article of the Future Project—

http://www.elsevier.com/about/mission/innovative-tools/article-of-the-future – Elsevier’s commitment to improve the reader’s experience with online articles—

enriched content, and interoperability with external databases – Linking of scientific journal publications with underlying and/or broader databases

available online—considered critical step in this transition — http://www.elsevier.com/about/content-innovation/database-linking

– caNanoLab is now reciprocally linked to several Elsevier journals (Google “Elsevier and caNanoLab;http://www.elsevier.com/about/press-releases/research-and-journals/elsevier-and-us-national-cancer-institute-implement-reciprocal-linking-between-research-articles-and-datasets) —e.g, Biomaterials, Journal of Controlled Release, Nanomedicine: Nanotechnology, Biology and Medicine

• New online Nature journal—Scientific Data, http://www.nature.com/sdata/

– Focuses on publishing descriptions of data and does so by working with repositories – Gives investigators credit for sharing data – caNanoLab listed as one of their recommended data repositories--

http://www.nature.com/sdata/data-policies/repositories – Editorial Board includes nanotechnology experts: Nathan Baker, Mark Viant

Data Sharing Outreach—Integrating Databases with Journals

19

Alliance Program Phase III • In addition to the Nanotechnology Characterization Laboratory, three different

components of the program:

NCI Alliance Phase III, 2015-2020

Centers of Cancer Nanotechnology Excellence

(CCNE) U54 Cooperative Agreement

RFA-CA-14-013 $2.6M/yr/award

5-6 CCNEs

Innovative Research in Cancer Nanotechnology

(IRCN) Awards U01 Cooperative Agreement

PAR-14-285 Next applications due October 15, 2015

T32 Cancer Nanotechnology Training Programs

Proposals received through PA-14-015 Next applications due September 25, 2015

$450K/yr/award Multiple Receipt Dates

Notice of NCI interest in Cancer Nano T32s—NOT-CA-14-035

• Initial awards for phase III of the NCI Alliance for Nanotechnology in Cancer program to be made in September 2015—six CCNEs, four IRCNs, and five T32 training programs

20

CCNE Characteristics

CCNEs are expected to (a) identify an overarching problem in cancer biology and/or oncology – a “Center Theme’ that can be addressed with a multi-project approach leveraging nanotechnology and (b) demonstrate the translational potential of the technologies proposed in the above mentioned projects. Expect each to be composed of several projects with a balance between discovery research and translational efforts. The overall goal is a rapid advance of novel cancer care applications based on nanotechnology.

21

IRCN U01 Awards

• Projects should be designed to enable multi-disciplinary research and transformative discoveries in cancer biology and/or oncology through the use of nanotechnology

• Funded projects become part of NCI Alliance for Nanotechnology in Cancer network. The network will provide opportunities for collaborations with other Alliance members and enhanced interactions with NCI programs

• If appropriate, work should aid in clinical translation, but clinical translation is not the ultimate goal of these awards

Projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize fundamental understanding of nanomaterial and nanodevice interactions with biological systems. Includes characterization of in vitro detection/diagnostic devices, research concerning delivery of nanoparticles/nanodevices to intended cancer targets in vivo.

Innovative Research in Cancer Nanotechnology

(IRCN) Awards U01 Cooperative Agreement

PAR-14-285; Next applications due October 15, 2015 $450K/yr/award

Two receipts/yr until 2017: April 14, October 13, 2016; April 14, 2017

Open to International Applicants!

No set-aside funds; Not percentiled

22

• Development of next generation nanoparticles • Understanding nanoparticle delivery mechanisms and implications of systemic

distribution • Techniques and tools to overcome failure of therapy • Tools and devices aimed specifically at monitoring the tumor microenvironment • Technologies suitable for biomarker discovery and screening • Development of improved multi-biomarker detection and diagnostic devices • Diagnostic nanoparticles/devices that preserve integrity of captured cells and

conformation of isolated molecules for downstream activity assays and analyses • Technologies for cancer molecular targeting, discovery, and validation • Devices and tools capable of penetrating cellular and/or physiological barriers • Integration of modeling and simulation approaches to guide rational nanomaterials

design Above examples are not meant to be comprehensive. Additional directions are also encouraged, providing they are consistent with general expectations of PAR

Possible Research Directions

23

Alliance Program Phase III: CCNEs and U01s • NCI intends to continue support for research in three broad areas of

nanotechnology-based cancer care applications: – early diagnosis using in vitro assays and devices or in vivo imaging techniques – multifunctional nano-therapeutics, including nanoparticle-driven immunotherapies – devices and techniques for cancer prevention and control

• Tumor Types: should be rationally selected, where “tumor type” refers to either tumors of a specific tissue of origin or tumors with critical abnormalities in a particular molecular pathway(s) shared in cancers arising from a variety of tissues.

• Milestones: applicants need to provide a set of discrete benchmarks that will allow unequivocal determination of the progress made towards the goals of the project.

• Data Sharing Plan: Sharing of nanomaterial data needs to occur through appropriate publically accessible databases: NCI’s cancer Nanotechnology Laboratory (caNanoLab) data portal (https://cananolab.nci.nih.gov/caNanoLab/)

– At least one scientifically qualified person needs to be designated as the nanomaterial data sharing coordinator after an award has been made

24

National Cancer Institute Organization: Related Programs and Initiatives

Division of Cancer Biology

Division of Cancer

Prevention

Division of Cancer

Control and Population Sciences

Division of Cancer

Treatment and

Diagnosis

Division of Extramural Activities

Division of Cancer

Epidemiology and Genetics

Center for Cancer

Research

Office of the Director

National Cancer Institute

Funding – Extramural Conducting – Intramural

Center for Strategic Scientific Initiatives

(CSSI)

Acting Director Douglas Lowy, MD

Mission: “…to create and uniquely implement exploratory programs focused on the development and integration of advanced technologies, trans-disciplinary approaches, infrastructures, and standards, to accelerate the creation and broad deployment of data, knowledge, and tools to empower the entire cancer research continuum in better understanding and leveraging knowledge of the cancer biology space for patient benefit…”

• CSSI, Office of the Director • Office of Cancer Clinical Proteomics Research • Office of Cancer Nanotechnology Research • The Cancer Genome Atlas • Office of Cancer Genomics • Office of Physical Sciences Oncology

Innovative Molecular Analysis Technologies

Provocative Questions

25

Innovative Molecular Analysis Technologies (IMAT) Program

Program Mission: To support the development, maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation in support of clinical, laboratory, or epidemiological research on cancer.

Proof of Principle

Advanced Development

Testing & Validation

Scale Up Dissemination

R21

R33

• Feasibility/Proof-of-principle study • Highly innovative technology • No preliminary data required

• Advanced development & validation phase • Demonstration of transformative utility • Requires proof of feasibility

Technology Development Pipeline

Concept

R43

• Feasibility study • Clear commercial

potential

R44

• Development & (regulatory) validation • Manufacturing & marketing plan • Requires proof of feasibility and

commercialization plan • Demonstration of transformative utility

SBIR Grant Mechanism (PAR-13-327)—Phase I, Phase II, and Fast-Track

≤$400k over 3 years direct cost support

≤$900k over 3 years direct cost support

≤ $225k over 6m total cost support

≤ $1.5M over 2 years total cost support

http://innovation.cancer.gov

26

Active IMAT Funding Opportunities

[R21] Innovative Technologies for Cancer-Relevant Biospecimen Sciences • FOA#: RFA-CA-15-004 • Budget: $400k/3yrs (direct cost cap)

[R33] Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Sciences • FOA#: RFA-CA-15-005 • Budget: $900k/3yrs (direct cost cap)

Molecular/Cellular

Analysis Tools

Sample QA/QC

Tools

[R21] Early‐Stage Innovative Molecular Analysis Technology Development for Cancer Research • FOA#: RFA-CA-15-002 • Budget: $400k/3yrs (direct cost cap)

[R33] Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research • FOA#: RFA-CA-15-003 • Budget: $900k/3yrs (direct cost cap)

27

IMAT Application Information Funding Instrument R21 & R33 Grants

Application Types Allowed

• New • Resubmission

Award Budget • R21: Direct costs are limited to $200,000 per year, and $400,000 in all direct costs over a 3-year period

• R33: Direct costs are limited to $300,000 per year, and $900,000 in all direct costs over a 3-year period.

Award Project Period The total project period is allowed for up to 3 years for all awards

Letter of Intent Due Date

August 22, 2015; Next cycle: January, May, August 2016

Application Due Date(s)

September 22, 2015; Next cycle: February, June, September 2016

Earliest Start Date(s) May 2016

Contact: Tony Dickherber dickherberaj@mail.nih.gov, nciimat@mail.nih.gov

28

Physical Sciences-Oncology Projects (PS-OP)

• Goal: conduct transdisciplinary research integrating the perspectives of physical scientists (e.g., engineers, chemists, computer scientists, mathematicians, physicists) and cancer researchers to address fundamental questions in cancer research using approaches and theories from the physical sciences.

• A cadre of U01 research projects will contribute to the collaborative Physical Sciences-Oncology Network, includes PS-Oncology Centers (U54s, PAR-14-169).

Contact: Nas Kuhn nas.kuhn@nih.gov

U01 mechanism up to $500K (DC)/year for up to 5 years (PAR-15-021) 1 Research Project Pilot/Trans-Network Projects

6 Receipt Dates – November 25, 2015; May 26, 2016; September 21, 2016; May 26, 2017; September 21, 2017

29

NCI Research Centers for Cancer Systems Biology Consortium (CSBC)

• The CSBC initiative aims to address challenges of complexity in basic and translational cancer research through the use of experimental biology combined with in silico modeling, multi-dimensional data analysis, and systems engineering.

• Expected to be composed of interdisciplinary teams of scientists (e.g., engineers, chemists, computer scientists) and cancer researchers

• The Consortium will consist of Research Centers, a Coordinating Center (RFA-CA-15-015), and U01 research projects.

Shannon Hughes shannon.hughes@nih.gov, Dan Gallahan dan.gallahan@nih.gov

U54 mechanism up to $1.5 M (DC)/year for 5 years (RFA-CA-15-014) 2-3 Research Projects 1 Administrative Core 0-2 Shared Resource Cores Outreach Core Pilot Projects

3 Receipt Dates – November 20, 2015; September 9, 2016; April 20, 2017

30

Enabling Biomimetic Tissue-Engineered Technologies for Integrative Cancer Research

• Upcoming Funding Opportunity (NOT-CA-15-026) - Cancer Tissue Engineering Collaborative (TEC) Research Program focusing on the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for understanding cancer biology, prevention, early detection, diagnosis and treatment.

• The Cancer TEC Research Program will spur collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, and biomaterials with cancer biology.

Contact: Nas Kuhn nas.kuhn@nih.gov

U01 mechanism 1 Research Project

Estimated Publication Date of Announcement: Winter 2015 First Estimated Application Due Date: March 2016

31

Bioengineering Research at NIH (Several Institutes)

• Bioengineering Research Partnerships, R01, PAR-14-092 – encourages bioengineering applications that will accelerate the development and

adoption of promising tools and technologies that can address important biomedical research problems

• Exploratory/Developmental Bioengineering Research Projects, R21,

PAR-12-284 – establish the feasibility…explore a unique multidisciplinary approach…are high-risk

but have a considerable pay-off… develop data which can lead to significant future research

• Parent R21, NCI R21 Omnibus, NCI R03 Omnibus

– PA-13-303, PAR-13-146, PAR-14-007

32

Even More Programs

• NIH Common Fund—Supports high risk research that is synergistic and cross-cutting—support for research, training, development of resources

– https://commonfund.nih.gov/

• Big Data to Knowledge (BD2K)—Common Fund project focused on developing new approaches, standards, methods, tools, software, and competencies to enhance use of biomed Big Data • http://bd2k.nih.gov

• NCI Informatics Technology for Cancer Research (ITCR)—Supports

investigator-initiated informatics technology development for the investigation and management of cancer • http://itcr.nci.nih.gov/

• All have available Funding Opportunity Announcements

33

Preparing an Application to NIH

• NIH Center for Scientific Review Applicant Resources – http://public.csr.nih.gov/ApplicantResources/Pages/default.aspx – NIH Peer Review Revealed – NIH Tips for Applicants – What Happens to Your NIH Grant Application – NIH Early Career Reviewer Program

• NIH RePORTER

– http://projectreporter.nih.gov/reporter.cfm – Search for applications; Institute, Program Officer, Study Section

• NIAID sample applications and summary statements – R01, R03, R21, R21/R33, R41, R42, R43, R44, F31 Diversity – http://www.niaid.nih.gov/researchfunding/grant/pages/appsamples.aspx

34

NIH Regional Seminar

• Interested in learning about the NIH grants process in-person? • Researchers, new or early career scientists, or research administrators

interested in learning more about applying for NIH grants, navigating NIH programs, and/or managing NIH awards can meet with ~ 50 NIH & HHS program, policy, grants management, and review experts at the 2015 NIH Regional Seminar in San Diego on October 14-16.

• http://regionalseminars.od.nih.gov/sandiego2015/

• http://nexus.od.nih.gov/all/2015/08/31/reminder-nih-regional-seminar-in-san-diego-october-14-16-2015/

• http://grants.nih.gov/grants/seminars.htm --learn about upcoming seminars here

35

Office of Cancer Nanotechnology Research

Consultants: Subhas Malghan – FDA Uma Prabhakar – formerly J&J

Dorothy Farrell Stephanie Morris Nicholas Panaro

Piotr Grodzinski

Christopher Hartshorn Natalie Abrams

http://www.nano.cancer.gov/ cancer.nano@mail.nih.gov

Christina Liu

36

Thank you!

Questions?

Stephanie Morris morriss2@mail.nih.gov